The characteristics of the positivity to the lactulose breath test in patients with abdominal bloating

Objectives The clinical utility in patients with bloating is still conflicting. We aimed to evaluate the positivity to lactulose breath test (LBT) in patients with bloating, and to assess the clinical characteristics according to the positivity or subtypes of LBT. Methods The patients with abdominal bloating undergoing LBT were investigated. Rome III positive irritable bowel syndrome (IBS) and bowel symptoms were surveyed according to the positivity or subtypes of LBT. Results The prevalence of IBS and the positivity to LBT was 23.8% (86 of 358) and 29.6% (106 of 358), respectively. The positivity to LBT and the prevalence in subtypes of LBT were not different according to the presence of IBS. The subtypes of LBT positive (+) patients were LBT (H2) with 61 (57.5%), (CH4)+ with 30 (28.3%), and (both) positive with 15 (14.2%). The LBT (H2)+ group was younger, and had higher symptomatic score for the bloating than that in the LBT negative (−) group. The LBT (CH4)+ group was older, and had higher scores of hard stool and strain than those of the LBT (−) group. In the fasting LBT (H2)+ group (n=37) diagnosed by increased baseline H2, the scores for abdominal discomfort, bloating, and flatus were higher than those for the LBT (H2)+ or LBT(−) groups. Conclusions The subtypes of the positivity to LBT according to the gas produced or the fasting H2 may contribute to specificity or severity of abdominal symptoms regardless of the presence of IBS.

[1]  S. Jung,et al.  Clinical Significance of Colonic Diverticulosis Associated with Bowel Symptoms and Colon Polyp , 2010, Journal of Korean medical science.

[2]  U. Ghoshal,et al.  Patients With Irritable Bowel Syndrome Exhale More Hydrogen Than Healthy Subjects in Fasting State , 2010, Journal of neurogastroenterology and motility.

[3]  R. McCallum,et al.  Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? , 2010, BMC gastroenterology.

[4]  U. Ghoshal,et al.  Frequency of Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome and Chronic Non-Specific Diarrhea , 2010, Journal of neurogastroenterology and motility.

[5]  P. Moayyedi,et al.  Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  U. Ghoshal,et al.  Epidemiology of irritable bowel syndrome in Asia: Something old, something new, something borrowed , 2009, Journal of gastroenterology and hepatology.

[7]  D. H. Lee,et al.  Quality of life of patients with irritable bowel syndrome in Korea , 2009, Quality of Life Research.

[8]  D. Drossman,et al.  Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[9]  M. Pimentel,et al.  The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome , 2006, Annals of Internal Medicine.

[10]  Myung-Gyu Choi,et al.  Cross-Cultural Validation of Irritable Bowel Syndrome Quality of Life in Korea , 2006, Digestive Diseases and Sciences.

[11]  Henry C. Lin,et al.  Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[12]  M. Simrén,et al.  Use and abuse of hydrogen breath tests , 2006, Gut.

[13]  R. Mounzer,et al.  A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence , 2006, The American Journal of Gastroenterology.

[14]  A. Gasbarrini,et al.  Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth , 2005, Alimentary pharmacology & therapeutics.

[15]  Henry C. Lin,et al.  Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. , 2004, JAMA.

[16]  S. Fukudo,et al.  Brain activity during distention of the descending colon in humans , 2004, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[17]  J. Romagnuolo,et al.  Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation , 2002, American Journal of Gastroenterology.

[18]  Henry C. Lin,et al.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome , 2000, American Journal of Gastroenterology.

[19]  G. Corazza,et al.  Non‐absorbable antibiotics for managing intestinal gas production and gas‐related symptoms , 2000, Alimentary pharmacology & therapeutics.

[20]  J. Liberman,et al.  Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. , 2000, Digestive diseases and sciences.

[21]  P. Kerlin,et al.  Breath hydrogen testing in bacterial overgrowth of the small intestine. , 1988, Gastroenterology.